Cystectomy for Transitional Cell Carcinoma of the Bladder: Results of a Surgery Only Series in the Neobladder Era

Abstract

In patients with organ confined, lymph node negative transitional cell carcinoma excellent survival data can be achieved as long as the tumor is limited to the inner half of the detrusor. These data on a large group of patients support early aggressive surgical management for invasive bladder cancer. The results of this surgery only series may serve as a reference for other treatment modalities for bladder cancer.

Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy

“…Hence, our median follow-up of 3.1 years should have been adequate to observe our intended endpoints. [2][3][4][5][6][7] Another potential limitation is the questionable reliability of immunohistochemical techniques. Immunohistochemistry is semiquantitative and highly dependent on a range of variables such as choice of antibody, antibody concentration, fixation techniques, variability in the interpretation and stratification criteria, and inconsistency in specimen handling and technical procedures.…”

“…Unfortunately, the 5-year all-cause survival rate in patients with pathologic muscle-invasive organ-confined UCB is only 60% to 75%. [2][3][4][5][6][7] Failure to cure these patients is often due to the presence of occult metastases at the time of primary local therapy.…”

Risk factors for upper tract urothelial recurrence following local excision of bladder cancer

“…Second, there is no doubt that radical cystectomy offers the best opportunity for ultimate cure of high‐grade and high‐risk invasive bladder cancer 12. Traditionally, radical cystectomy is recommended for the majority of patients with muscle‐invasive bladder cancer (T2‐T4a, N0‐Nx, M0) with a curative intent 13. In addition, patients who underwent local excision of their bladder tumor in this study had a lower tumor grade than patients who underwent radical cystectomy.…”

Survival of patients with bladder cancer after radical cystectomy

“…Современные исследования де-монстрируют 5-летнюю ОВ после РЦЭ без дополнитель-ных методов лечения в диапазоне 48-58 % [2,11,12,19]. Большинство рецидивов возникают в течение первых 3 лет.…”

“…Онкологические результаты РЦЭ зависят от ряда клинических и патоморфологических характеристик: неоадъювантная химиолучевая терапия, предшеству-ющая трансуретральная резекция (ТУР) опухоли, степень ее инвазии, наличие или отсутствие метаста-тического поражения регионарных ЛУ, степень диф-ференцировки опухоли [4,[9][10][11][12]. Большинство ре-цидивов после РЦЭ возникают в первые 2-3 года после операции, местные рецидивы с частотой 4-29 % и отдаленные с частотой 22-38 % от общего числа больных [13][14][15][16].…”